NCT04746963View on ClinicalTrials.gov

Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

October 1, 2022

Study Completion Date

October 1, 2022

Conditions
Neovascular Age-Related Macular Degeneration (nAMD)
Interventions
DRUG

AXT107 0.1 mg

Single intravitreal injection of AXT107 0.1 mg/eye (low dose)

DRUG

AXT107 0.25 mg

Single intravitreal injection of AXT107 0.25 mg/eye (mid dose)

DRUG

AXT107 0.5 mg

Single intravitreal injection of AXT107 0.5 mg/eye (high dose)

Trial Locations (10)

19006

AsclepiX Investigative Site, Huntingdon Valley

33711

AsclepiX Investigative Site, St. Petersburg

77384

AsclepiX Investigative Site, The Woodlands

78503

AsclepiX Investigative Site, McAllen

79606

AsclepiX Investigative Site, Abilene

85053

AsclepiX Investigative Site, Gilbert

89502

AsclepiX Investigative Site, Reno

90211

AsclepiX Investigative Site, Los Angeles

97401

AsclepiX Investigative Site, Eugene

02114

AsclepiX Investigative Site, Boston

Sponsors
All Listed Sponsors
lead

AsclepiX Therapeutics, Inc.

INDUSTRY

NCT04746963 - Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration | Biotech Hunter | Biotech Hunter